In this section
@article{Mullish:2024:10.1097/HEP.0000000000000986,
author = {Mullish, BH and Thursz, MR},
doi = {10.1097/HEP.0000000000000986},
journal = {Hepatology},
title = {Alcohol-associated liver disease: Emerging therapeutic strategies.},
url = {http://dx.doi.org/10.1097/HEP.0000000000000986},
year = {2024}
}
TY - JOUR
AB - The large and growing burden of alcohol-associated liver disease-and the considerable burden of morbidity and mortality associated with it-has been a drive toward ongoing research into novel strategies for its treatment, with a particular focus upon alcohol-associated hepatitis (AH). Management of alcohol-use disorder forms the central pillar of alcohol-associated liver disease care, with evidence-based psychological and pharmacological approaches being well established, and certain models demonstrating improved clinical outcomes when hepatology and addiction services are co-located. Corticosteroids have previously been used somewhat indiscriminately in patients with severe AH, but effective tools now exist to assess early response (and limit futile ongoing exposure). Techniques to predict risk of corticosteroid-related infection are also available, although current clinical strategies to mitigate this risk are limited. A variety of novel therapeutic approaches to AH are at different phases of trials and evidence gathering, with some of the most promising signals related to cytokine manipulation, epigenetic modulation, and targeting of the gut microbiota (ie, by means of fecal microbiota transplant). While remaining an ongoing source of debate, early liver transplant in severe AH has grown in interest and acceptability over the past decade as evidence supporting its efficacy builds, in the process challenging paradigms about mandatory pretransplant sobriety periods. However, uncertainty remains regarding the optimal selection criteria, and whether liver transplant has a role for only a highly limited proportion of patients with AH or more widespread application. This review aims to provide an overview of this fast-moving field.
AU - Mullish,BH
AU - Thursz,MR
DO - 10.1097/HEP.0000000000000986
PY - 2024///
TI - Alcohol-associated liver disease: Emerging therapeutic strategies.
T2 - Hepatology
UR - http://dx.doi.org/10.1097/HEP.0000000000000986
UR - https://www.ncbi.nlm.nih.gov/pubmed/38922808
UR - http://hdl.handle.net/10044/1/112682
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: